SCHEMBL6942607

SCHEMBL6942607

CCc1cnc(Cc2ccc3c(c2)OCO3)nc1O

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP3A4 P08684 2/20 0.45
IGFBP3 P17936 1/20 0.45
ALDH1A1 P00352 3/20 0.44
HSD17B10 Q99714 1/20 0.44
LTB4R Q15722 1/20 0.43
MEN1 O00255 1/20 0.43
KMT2A Q03164 1/20 0.43
CYP1A2 P05177 1/20 0.43
CYP2C19 P33261 1/20 0.43
SMN1; SMN2 Q16637 1/20 0.42
HDAC3 O15379 1/20 0.42
HDAC1 Q13547 1/20 0.42
HDAC2 Q92769 1/20 0.42
HDAC6 Q9UBN7 1/20 0.42
CYP2D6 P10635 1/20 0.42
SLC6A2 P23975 1/20 0.42
SLC6A4 P31645 1/20 0.42
SLC6A3 Q01959 1/20 0.42
CALM1 P0DP23 1/20 0.42
TAAR1 Q96RJ0 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6946706 0.87 ALDH1A1 (0.44) CYP3A4ALDH1A1HSD17B10LTB4RSMN1; SMN2
SCHEMBL6943649 0.86 SMN1; SMN2 (0.42) CYP3A4ALDH1A1HSD17B10MEN1KMT2A
SCHEMBL6942002 0.86 CALM1 (0.45) CYP3A4IGFBP3ALDH1A1HSD17B10LTB4R
SCHEMBL6941106 0.85 SMN1; SMN2 (0.47) CYP3A4IGFBP3ALDH1A1HSD17B10MEN1
SCHEMBL6945057 0.84 ALDH1A1 (0.46) CYP3A4IGFBP3ALDH1A1HSD17B10LTB4R
SCHEMBL6939898 0.84 GAA (0.49) CYP3A4ALDH1A1MEN1KMT2ACALM1
SCHEMBL6942379 0.82 TSHR (0.47) CYP3A4ALDH1A1HSD17B10MEN1KMT2A
SCHEMBL6941230 0.82 NPC1 (0.46) CYP3A4IGFBP3ALDH1A1MEN1KMT2A
SCHEMBL28066233 0.81 ALDH1A1 (0.48) CYP3A4ALDH1A1HSD17B10LTB4RMEN1
SCHEMBL6942293 0.81 ALDH1A1 (0.51) CYP3A4IGFBP3ALDH1A1HSD17B10LTB4R

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1268471-B1 N-HETEROCYCLIC DERIVATIVES AS NOS INHIBITORS SCHERING AG (DE) 2003-10-15 EP disclosed
US-6525051-B2 N-heterocyclic derivatives as NOS inhibitors SCHERING AKTIENGESELLSCHAFT (DE) 2003-02-25 US disclosed
US-20020010190-A1 N-heterocyclic derivatives as NOS inhibitors SCHERING AKTIENGESELLSCHAFT (DE) 2002-01-24 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020010190-A1 N-heterocyclic derivatives as NOS inhibitors NOS1, NOS3, NOS2 CYP3A4 46/4885IGFBP3 4000/4885ALDH1A1 573/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.